Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) will host a conference call on March 17, 2022, at 8:30 a.m. ET to provide a corporate update and discuss financial results for Q4 and the full year ended December 31, 2021. Investors can join via phone or through a live webcast on Avadel’s website, which will be available for replay for 90 days. The company focuses on innovative medication solutions, particularly its investigational drug candidate FT218 aimed at treating narcolepsy-related excessive daytime sleepiness and cataplexy.

Positive

• Company to discuss financial results, providing transparency to investors.
• Lead drug candidate FT218 addresses significant market need for narcolepsy treatment.

Negative

• None.

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 17, 2022, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2021.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 1878871. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

When is the Avadel Pharmaceuticals conference call?

The conference call is scheduled for March 17, 2022, at 8:30 a.m. ET.

What financial results will Avadel Pharmaceuticals discuss?

Avadel will discuss its fourth quarter and full year financial results for 2021.

How can I access the Avadel Pharmaceuticals conference call?

You can access the call by dialing (844) 388-0559 for U.S. and Canada or (216) 562-0393 internationally, using conference ID 1878871, or via the live webcast on their website.

What is FT218 and its purpose?

FT218 is an investigational formulation of sodium oxybate aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.